376 related articles for article (PubMed ID: 36196486)
1. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma.
van den Ende T; van der Pol Y; Creemers A; Moldovan N; Boers D; van Berge Henegouwen MI; Hulshof MC; Cillessen SA; van Grieken NC; Pegtel DM; Derks S; Bijlsma MF; Mouliere F; van Laarhoven HW
J Pathol; 2023 Nov; 261(3):286-297. PubMed ID: 37615198
[TBL] [Abstract][Full Text] [Related]
4. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
[TBL] [Abstract][Full Text] [Related]
6. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.
Vollenbrock SE; van Dieren JM; Voncken FEM; van Turenhout ST; Kodach LL; Hartemink KJ; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur Radiol; 2020 May; 30(5):2425-2434. PubMed ID: 31965258
[TBL] [Abstract][Full Text] [Related]
7. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
8. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
9. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
[TBL] [Abstract][Full Text] [Related]
10. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
[TBL] [Abstract][Full Text] [Related]
14. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
15. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer.
Hofste LSM; Geerlings MJ; von Rhein D; Rütten H; Westenberg AH; Weiss MM; Gilissen C; Hofste T; van der Post RS; Klarenbeek BR; de Wilt JHW; Ligtenberg MJL;
Eur J Surg Oncol; 2023 Jul; 49(7):1283-1290. PubMed ID: 36740555
[TBL] [Abstract][Full Text] [Related]
17. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
[TBL] [Abstract][Full Text] [Related]
19. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response.
Pazdirek F; Minarik M; Benesova L; Halkova T; Belsanova B; Macek M; Stepanek L; Hoch J
Front Oncol; 2020; 10():1028. PubMed ID: 32793464
[No Abstract] [Full Text] [Related]
[Next] [New Search]